{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:00:09Z","timestamp":1785362409604,"version":"3.55.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cll.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:17:42Z","timestamp":1785359862000},"page":"577-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["All Together Now"],"prefix":"10.1016","volume":"46","author":[{"given":"Pari","family":"Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Setia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2026.06.011_bib1","first-page":"426","article-title":"Karzinoide tumoren des dunndarms","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Z Pathol"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.humpath.2004.09.018","article-title":"Siegfried Oberndorfer: origins and perspectives of carcinoid tumors","volume":"35","author":"Modlin","year":"2004","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000096997","article-title":"Evolution of the diffuse neuroendocrine system: clear cells and cloudy origins","volume":"84","author":"Modlin","year":"2006","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12022-007-0021-9","article-title":"Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma","volume":"18","author":"Kl\u00f6ppel","year":"2007","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.cll.2026.06.011_bib5","series-title":"The spectrum of neuroendocrine neoplasia: a practical approach to diagnosis, classification and therapy","first-page":"1","article-title":"Neuroendocrine neoplasms: historical background and terminologies","author":"Asa","year":"2021"},{"key":"10.1016\/j.cll.2026.06.011_bib6","series-title":"Pulmonary endocrine pathology: endocrine cells and endocrine tumours of the lung","first-page":"6","article-title":"Identification, morphology, and secretory products of the pulmonary endocrine system","author":"Gosney","year":"1992"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.cll.2026.06.011_bib8","series-title":"Endocrine and neuroendocrine tumours","year":"2022"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.21037\/jgo.2020.03.11","article-title":"Genetic and epigenetic alterations in pancreatic neuroendocrine tumors","volume":"11","author":"Tirosh","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.cll.2026.06.011_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.humpath.2019.12.002","article-title":"Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?","volume":"96","author":"Bellizzi","year":"2020","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/cncy.21765","article-title":"Algorithmic approach to neuroendocrine tumors in targeted biopsies: practical applications of immunohistochemical markers","volume":"124","author":"Duan","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.cll.2026.06.011_bib15","series-title":"Thoracic tumours","year":"2022"},{"key":"10.1016\/j.cll.2026.06.011_bib16","series-title":"Digestive system tumours","year":"2019"},{"key":"10.1016\/j.cll.2026.06.011_bib17","series-title":"Head and neck tumours","year":"2022"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JTO.0000000000000092","article-title":"Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice","volume":"9","author":"Pelosi","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cll.2026.06.011_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5858\/arpa.2019-0665-RA","article-title":"What is new in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing","volume":"145","author":"Assarzadegan","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12105-022-01435-8","article-title":"Update from the 5th edition of the World Health Organization Classification of Head and Neck Tumors: overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms","volume":"16","author":"Mete","year":"2022","journal-title":"Head Neck Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12022-020-09628-z","article-title":"Morphologic variants of pancreatic neuroendocrine tumors: clinicopathologic analysis and prognostic stratification","volume":"31","author":"Xue","year":"2020","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4143\/crt.2019.192","article-title":"Pancreatic high-grade neuroendocrine neoplasms in the Korean population: a multicenter study","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/1097-0142(1971)28:4<990::AID-CNCR2820280424>3.0.CO;2-K","article-title":"Pathologic analysis of carcinoids: histologic re-evaluation of 62 cases","volume":"28","author":"Soga","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.cll.2026.06.011_bib26","series-title":"WHO classification of tumours of the digestive system","year":"2010"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib27","article-title":"Revised classification of neuroendocrine tumours of the lung, pancreas and gut","volume":"425","author":"Capella","year":"1995","journal-title":"Virchows Archiv A Pathol Anat"},{"issue":"11","key":"10.1016\/j.cll.2026.06.011_bib28","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1200\/JCO.2002.10.030","article-title":"Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups","volume":"20","author":"Hochwald","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.cll.2026.06.011_bib30","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.cll.2026.06.011_bib31","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-16-3135","article-title":"RB loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study","volume":"23","author":"Hijioka","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.cll.2026.06.011_bib32","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Rel Cancer"},{"issue":"10","key":"10.1016\/j.cll.2026.06.011_bib36","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/MPA.0000000000001693","article-title":"Concordance between the Ki-67 index cutoff value of 55% and differentiation in neuroendocrine tumor and neuroendocrine carcinoma in grade 3 pancreatic neuroendocrine neoplasms","volume":"49","author":"Shi","year":"2020","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"4_suppl","key":"10.1016\/j.cll.2026.06.011_bib38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2020.38.4_suppl.622","article-title":"Treatment outcomes of patients with G3 neuroendocrine neoplasms [abstract only]","volume":"38","author":"Jann","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MPA.0000000000000735","article-title":"Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated","volume":"46","author":"Raj","year":"2017","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12022-014-9316-9","article-title":"High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back","volume":"25","author":"La Rosa","year":"2014","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib41","doi-asserted-by":"crossref","first-page":"17947","DOI":"10.1038\/s41598-021-97247-x","article-title":"Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort","volume":"11","author":"Lithgow","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cll.2026.06.011_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.humpath.2018.03.018","article-title":"Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3","volume":"77","author":"Konukiewitz","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cll.2026.06.011_bib43","series-title":"WHO classification of tumours of endocrine organs","year":"2017"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000494355","article-title":"Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study","volume":"107","author":"Rindi","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.cll.2026.06.011_bib45","first-page":"467","article-title":"Borderline\u201d neuroendocrine carcinomas of the lung are clinically and genomically distinct from large-cell neuroendocrine carcinoma [abstract only]","volume":"29","author":"Vivero","year":"2016","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF03033739","article-title":"Endobronchial large-cell neuroendocrine carcinoma","volume":"9","author":"Megyesi","year":"2003","journal-title":"Pathol Oncol Res"},{"issue":"14","key":"10.1016\/j.cll.2026.06.011_bib47","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large-cell neuroendocrine carcinoma reveals small-cell carcinoma-like and non-small-cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13000-019-0886-1","article-title":"Two cases of lung neuroendocrine carcinoma with carcinoid morphology","volume":"14","author":"Inafuku","year":"2019","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.cll.2026.06.011_bib49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.lungcan.2020.10.015","article-title":"Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature","volume":"150","author":"Hermans","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12885-022-09391-w","article-title":"Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large-cell neuroendocrine carcinoma","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.cll.2026.06.011_bib51","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41379-020-0538-8","article-title":"Transcriptomic data helps refining classification of pulmonary carcinoid tumors with increased mitotic counts","volume":"33","author":"Sazonova","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PAS.0000000000000767","article-title":"High-grade neuroendocrine carcinoma of the lung with carcinoid morphology: a study of 12 cases","volume":"41","author":"Quinn","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.cll.2026.06.011_bib53","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/00000478-200209000-00009","article-title":"Small-cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens","volume":"26","author":"Nicholson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2026.06.011_bib54","doi-asserted-by":"crossref","first-page":"vii65","DOI":"10.1093\/annonc\/mdq380","article-title":"Advances in neuroendocrine lung tumors","volume":"21","author":"Travis","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib55","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/modpathol.2011.150","article-title":"Update on small-cell carcinoma and its differentiation from squamous cell carcinoma and other non-small-cell carcinomas","volume":"25","author":"Travis","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.amjsurg.2020.12.037","article-title":"Pancreatic neuroendocrine tumors: surgical outcomes and survival analysis","volume":"221","author":"Fahmy","year":"2021","journal-title":"Am J Surg"},{"key":"10.1016\/j.cll.2026.06.011_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13019-016-0424-0","article-title":"Outcomes after surgical resection of pulmonary carcinoid tumors","volume":"11","author":"Okereke","year":"2016","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.cll.2026.06.011_bib58","doi-asserted-by":"crossref","first-page":"679000","DOI":"10.3389\/fendo.2021.679000","article-title":"Role of somatostatin receptor in pancreatic neuroendocrine tumor development, diagnosis, and therapy","volume":"12","author":"Hu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.cll.2026.06.011_bib59","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cll.2026.06.011_bib60","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2147\/OTT.S202867","article-title":"Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights","volume":"13","author":"Starr","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2021.10613","article-title":"The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5","volume":"22","author":"Popa","year":"2021","journal-title":"Exp Ther Med"},{"issue":"11","key":"10.1016\/j.cll.2026.06.011_bib63","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/j.1582-4934.2010.01125_1.x","article-title":"Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2\u2013\u2013clinical implications","volume":"14","author":"Cakir","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"28","key":"10.1016\/j.cll.2026.06.011_bib64","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0033-1333651","article-title":"Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases","volume":"30","author":"Gupta","year":"2013","journal-title":"Semin Intervent Radiol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib67","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-14-0630","article-title":"GEP-NETs update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs","volume":"172","author":"Baere","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib68","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/jcm10061267","article-title":"Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review","volume":"10","author":"Camus","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib69","doi-asserted-by":"crossref","first-page":"e0158140","DOI":"10.1371\/journal.pone.0158140","article-title":"Systematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET)","volume":"11","author":"Wong","year":"2016","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib70","doi-asserted-by":"crossref","first-page":"457","DOI":"10.21037\/jgo.2016.12.09","article-title":"Biologics in gastrointestinal and pancreatic neuroendocrine tumors","volume":"8","author":"Liu","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"10.1016\/j.cll.2026.06.011_bib71","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib72","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib73","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small-cell lung cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"AKP","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cll.2026.06.011_bib74","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3389\/fonc.2020.01074","article-title":"Update on the biology, management, and treatment of small-cell lung cancer (SCLC)","volume":"10","author":"Saltos","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib75","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaoncol.2020.8072","article-title":"Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas: a review","volume":"7","author":"Stelwagen","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib76","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ctrv.2008.10.007","article-title":"Clinical and therapeutic aspects of extrapulmonary small-cell carcinoma","volume":"35","author":"Walenkamp","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib77","first-page":"CD011917","article-title":"Surgery for limited-stage small-cell lung cancer","volume":"2017","author":"Barnes","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cll.2026.06.011_bib78","doi-asserted-by":"crossref","first-page":"650293","DOI":"10.3389\/fonc.2021.650293","article-title":"Large-cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities","volume":"11","author":"Ferrara","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cll.2026.06.011_bib79","doi-asserted-by":"crossref","first-page":"653162","DOI":"10.3389\/fonc.2021.653162","article-title":"Management of large-cell neuroendocrine carcinoma","volume":"11","author":"Corbett","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib80","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.thorsurg.2014.05.001","article-title":"Large-cell neuroendocrine carcinoma of the lung: surgical management","volume":"24","author":"Sakurai","year":"2014","journal-title":"Thorac Surg Clin"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib81","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.jtho.2019.09.005","article-title":"Outcomes for surgery in large-cell lung neuroendocrine cancer","volume":"14","author":"Raman","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cll.2026.06.011_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667468","article-title":"Treatment of advanced-stage large-cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases","volume":"11","author":"Atieh","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","article-title":"Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome","volume":"24","author":"Derks","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib84","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41467-018-03099-x","article-title":"Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors","volume":"9","author":"George","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib85","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1078-0432.CCR-16-0355","article-title":"Genomic profiling of large-cell neuroendocrine carcinoma of the lung","volume":"23","author":"Miyoshi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib86","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr.2020.02.13","article-title":"Multiple faces of pulmonary large-cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis","volume":"9","author":"Baine","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cll.2026.06.011_bib87","doi-asserted-by":"crossref","first-page":"653153","DOI":"10.3389\/fonc.2021.653153","article-title":"Prevalence of TP-53\/RB-1 co-mutation in large-cell neuroendocrine carcinoma","volume":"11","author":"Saghaeiannejad Esfahani","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib88","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","article-title":"The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma","volume":"26","author":"Zhuo","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small-cell and large-cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib90","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib91","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D","volume":"241","author":"Simbolo","year":"2017","journal-title":"J Pathol"},{"issue":"209","key":"10.1016\/j.cll.2026.06.011_bib92","first-page":"209ra153","article-title":"A genomics-based classification of human lung tumors","volume":"5","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib93","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0002-9440(10)65653-2","article-title":"Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization","volume":"153","author":"Walch","year":"1998","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib94","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/JME-12-0069","article-title":"Molecular pathology and genetics of pancreatic endocrine tumours","volume":"49","author":"Capurso","year":"2012","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib95","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cancergencyto.2004.04.015","article-title":"Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors","volume":"156","author":"Floridia","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"7643","key":"10.1016\/j.cll.2026.06.011_bib96","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"6021","key":"10.1016\/j.cll.2026.06.011_bib97","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib98","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1677\/ERC-10-0028","article-title":"MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases","volume":"17","author":"Corbo","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"15_suppl","key":"10.1016\/j.cll.2026.06.011_bib99","doi-asserted-by":"crossref","first-page":"e15661","DOI":"10.1200\/JCO.2016.34.15_suppl.e15661","article-title":"Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): a study using MSK-IMPACT","volume":"34","author":"Raj","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6041","key":"10.1016\/j.cll.2026.06.011_bib100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib101","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib102","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","article-title":"Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib103","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"Singhi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.cll.2026.06.011_bib104","doi-asserted-by":"crossref","first-page":"49796","DOI":"10.18632\/oncotarget.17964","article-title":"DAXX\/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib105","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","article-title":"ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup","volume":"9","author":"Chan","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.cll.2026.06.011_bib106","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncy.22457","article-title":"Prognostic biomarkers in pancreatic neuroendocrine tumors","volume":"129","author":"Heaphy","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib107","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jtho.2018.02.002","article-title":"New insights into the molecular characteristics of pulmonary carcinoids and large-cell neuroendocrine carcinomas, and the impact on their clinical management","volume":"13","author":"Derks","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"Suppl 9","key":"10.1016\/j.cll.2026.06.011_bib108","doi-asserted-by":"crossref","first-page":"S1194","DOI":"10.21037\/jtd.2019.03.66","article-title":"Exploring the molecular and biological background of lung neuroendocrine tumours","volume":"11","author":"Simbolo","year":"2019","journal-title":"J Thorac Dis"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib109","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"27","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.cll.2026.06.011_bib110","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/hmg\/6.13.2285","article-title":"Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung","volume":"6","author":"Debelenko","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib111","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1210\/jc.2013-2782","article-title":"MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids","volume":"99","author":"Swarts","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib112","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/his.13394","article-title":"Molecular alterations of neuroendocrine tumours of the lung","volume":"72","author":"Rossi","year":"2018","journal-title":"Histopathology"},{"issue":"7563","key":"10.1016\/j.cll.2026.06.011_bib113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small-cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cll.2026.06.011_bib114","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib115","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"Small-cell lung carcinoma subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small-cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib117","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","article-title":"ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs","volume":"16","author":"Borromeo","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.cll.2026.06.011_bib118","doi-asserted-by":"crossref","first-page":"779276","DOI":"10.3389\/fonc.2022.779276","article-title":"Prognostic implications of molecular subtypes in primary small-cell lung cancer and their correlation with cancer immunity","volume":"12","author":"Qi","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib119","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An algorithmic immunohistochemical approach to define tumor type and assign site of origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv Anat Pathol"},{"issue":"11","key":"10.1016\/j.cll.2026.06.011_bib120","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1097\/PAS.0000000000000916","article-title":"INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity","volume":"41","author":"Rooper","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib121","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1309\/AJCPGZWXXBSNL4VD","article-title":"INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms","volume":"144","author":"Rosenbaum","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib122","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12022-020-09645-y","article-title":"Clinical routine application of the second-generation neuroendocrine markers ISL2, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin","volume":"31","author":"Juhlin","year":"2020","journal-title":"Endocr Pathol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib123","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAP.0b013e3182a2dc67","article-title":"Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry","volume":"20","author":"Bellizzi","year":"2013","journal-title":"Adv Anat Pathol"},{"issue":"9","key":"10.1016\/j.cll.2026.06.011_bib124","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamasurg.2014.216","article-title":"Neuroendocrine tumors of unknown primary: is the primary site really not known?","volume":"149","author":"Bergsland","year":"2014","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib125","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/030089161109700504","article-title":"Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?","volume":"97","author":"Catena","year":"2011","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.cll.2026.06.011_bib126","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000448431","article-title":"Professional practices and diagnostic issues in neuroendocrine tumour pathology: results of a prospective one-year survey among French pathologists (the PRONET study)","volume":"105","author":"Scoazec","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib127","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/PAS.0b013e31824aba59","article-title":"PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms","volume":"36","author":"Chan","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1385\/EP:15:3:247","article-title":"CDX2 as a marker for neuroendocrine tumors of unknown primary sites","volume":"15","author":"Erickson","year":"2004","journal-title":"Endocr Pathol"},{"issue":"7","key":"10.1016\/j.cll.2026.06.011_bib129","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/modpathol.2013.40","article-title":"ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin","volume":"26","author":"Agaimy","year":"2013","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/PAI.0000000000000563","article-title":"Clusterin in neuroendocrine epithelial neoplasms: absence of expression in a well-differentiated tumor suggests a jejunoileal origin","volume":"26","author":"Czeczok","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib131","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.cll.2026.06.011_bib132","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/PAS.0000000000000089","article-title":"Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate","volume":"37","author":"McCall","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"2\u20133","key":"10.1016\/j.cll.2026.06.011_bib133","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000369275","article-title":"Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential","volume":"100","author":"van Velthuysen","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib134","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2559.1996.d01-509.x","article-title":"Heterogeneity of mitotic activity in breast cancer","volume":"29","author":"Jannink","year":"1996","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2559.1990.tb00789.x","article-title":"Comparison of cell growth in different parts of breast cancers","volume":"17","author":"Verhoeven","year":"1990","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib136","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","article-title":"Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification","volume":"35","author":"Yang","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib137","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/modpathol.2008.177","article-title":"Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors","volume":"22","author":"Couvelard","year":"2009","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.cll.2026.06.011_bib138","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41379-021-00825-7","article-title":"Counting mitoses: SI(ze) matters","volume":"34","author":"Cree","year":"2021","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib139","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.anndiagpath.2013.05.005","article-title":"Are we counting mitoses correctly?","volume":"17","author":"Yigit","year":"2013","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.011_bib140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/106689690501300205","article-title":"A proposal for the adoption of a uniform metrical system for mitosis counting","volume":"13","author":"Facchetti","year":"2005","journal-title":"Int J Surg Pathol"},{"issue":"7","key":"10.1016\/j.cll.2026.06.011_bib141","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1369\/0022155417708186","article-title":"Grading and prognostication of neuroendocrine tumors of the pancreas: a comparison study of Ki67 and PHH3","volume":"65","author":"Tracht","year":"2017","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.cll.2026.06.011_bib142","first-page":"e1013640","article-title":"Identification of phosphohistone H3 cutoff values corresponding to original WHO grades but distinguishable in well-differentiated gastrointestinal neuroendocrine tumors","volume":"2018","author":"Kim","year":"2018","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.cll.2026.06.011_bib143","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/modpathol.2014.156","article-title":"Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies","volume":"28","author":"Reid","year":"2015","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.cll.2026.06.011_bib144","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/PAS.0b013e318263207c","article-title":"Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods","volume":"36","author":"Tang","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.cll.2026.06.011_bib145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PAI.0000000000000934","article-title":"Digital image analysis of the proliferation markers Ki67 and phosphohistone H3 in gastroenteropancreatic neuroendocrine neoplasms: accuracy of grading compared with routine manual hot spot evaluation of the Ki67 index","volume":"29","author":"Lea","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib146","doi-asserted-by":"crossref","first-page":"152753","DOI":"10.1016\/j.prp.2019.152753","article-title":"Potential pitfalls in diagnostic digital image analysis: experience with Ki-67 and PHH3 in gastrointestinal neuroendocrine tumors","volume":"216","author":"Hacking","year":"2020","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.cll.2026.06.011_bib147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/jpi.jpi_76_18","article-title":"Ki67 quantitative interpretation: insights using image analysis","volume":"10","author":"Volynskaya","year":"2019","journal-title":"J Pathol Inform"},{"issue":"9","key":"10.1016\/j.cll.2026.06.011_bib148","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/modpathol.2012.81","article-title":"Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors","volume":"25","author":"Walts","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.011_bib149","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-012-1194-2","article-title":"Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach","volume":"460","author":"Zahel","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cll.2026.06.011_bib150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fendo.2011.00020","article-title":"Partitioning of bronchopulmonary carcinoids in two different prognostic categories by Ki-67 score","volume":"2","author":"Grimaldi","year":"2011","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.cll.2026.06.011_bib151","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JTO.0b013e3181ca063b","article-title":"ERCC1 and Ki67 in small-cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival","volume":"5","author":"Skov","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.011_bib152","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1309\/QYV05VGEGKUL2RTT","article-title":"Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact","volume":"123","author":"Aslan","year":"2005","journal-title":"Am J Clin Pathol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:48:04Z","timestamp":1785361684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":152,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272271226000569"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.06.011","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All Together Now","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}